Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib and Isoquercetin in Hospitalized Moderate/Severe COVID-19
NCT04622865Phase 2Unknown
- Sponsor
- AB Science
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Masitinib + Isoquercetin + BSC with Best Supportive Care (2 arms). Primary endpoint: Clinical status of patients using a 7-point ordinal scale at Day 15. Status: unknown.
02
Drugs
masitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04622865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622865.